Oxford BioMedica 2016 LentiVector Gene Therapy Platform

Oxford BioMedica presents its LentiVector® lentiviral vector delivery platform for gene and cell therapy applications. The presentation covers clinical data from cohort studies, product portfolio including in-licensing partnerships with Sanofi, Novartis, and GSK, and proprietary bioprocessing capabilities for ex vivo cell therapies.